EMBLAVEO Drug Patent Profile

Which patents cover Emblaveo, and what generic alternatives are available?

Emblaveo is a drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and ninety-five patent family members in fifty-five countries.

The generic ingredient in EMBLAVEO is avibactam sodium; aztreonam. One supplier is listed for this compound. Additional details are available on the avibactam sodium; aztreonam profile page.

DrugPatentWatch^® Generic Entry Outlook for Emblaveo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 7, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EMBLAVEO

International Patents:	195
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in EMBLAVEO?	EMBLAVEO excipients list
DailyMed Link:	EMBLAVEO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EMBLAVEO

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

217906

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EMBLAVEO

Drug Class	Monobactam Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for EMBLAVEO

EMBLAVEO is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes			Y	Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes				Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes			Y	Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes				Y

Expired US Patents for EMBLAVEO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025

International Patents for EMBLAVEO

When does loss-of-exclusivity occur for EMBLAVEO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EMBLAVEO around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	201317238	Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1-,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Montenegro	00060	NOVA HETEROCIKLIČNA JEDINJENJA, NJIHOVO DOBIJANJE I NJIHOVA UPOTREBA KAO MEDIKAMENATA, A NAROČITO KAO ANTI-BAKTERIJSKIH AGENASA (AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS)
Russian Federation	2014101244	СПОСОБ ПОЛУЧЕНИЯ ГЕТЕРОЦИКЛИЧЕСКИХ СОЕДИНЕНИЙ, ВКЛЮЧАЯ ТРАНС-7-ОКСО-6-(СУЛЬФООКСИ)-1, 6-ДИАЗАБИЦИКЛО[3,2,1]ОКТАН-2-КАРБОКСАМИД И ЕГО СОЛИ
Eurasian Patent Organization	004920	АЗАБИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, В ЧАСТНОСТИ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ (AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS)
Spain	2401855

Supplementary Protection Certificates for EMBLAVEO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1480644	629	Finland
1480644	2016C/069	Belgium		PRODUCT NAME: ZAVICEFTA (COMBINAISON DE CEFTAZIDIME ET AVIBACTAM); AUTHORISATION NUMBER AND DATE: EU/1/16/1109/001 20160628
1480644	300847	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
1480644	132016000125850	Italy		PRODUCT NAME: MISCELA O ASSOCIAZIONE FARMACEUTICA CHE COMPRENDE COME PRINCIPI ATTIVI: (1) CEFTAZIDIMA O UN SUO SALE, E (2) AVIBACTAM O UN SUO SALE(ZAVICEFTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1109, 20160628
1480644	1690059-9	Sweden		PRODUCT NAME: PHARMACEUTICAL MIXTURE OR ASSOCIATION THAT INCLUDES AS ACTIVE INGREDIENTS: (1) CEFTAZIDIME OR A SALT THEREOF, AND (2) AVIBACTAM OR A SALT THEREOF; REG. NO/DATE: EU/1/16/1109 20160628

EMBLAVEO: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

EMBLAVEO, a new gene therapy for pediatric patients with GATA2 deficiency, presents a significant market opportunity driven by unmet medical need and limited treatment options. Developed by APEC, a subsidiary of Takeda Pharmaceutical Company, EMBLAVEO targets the underlying genetic cause of the disease, offering potential for long-term disease modification. This analysis examines the market landscape, competitive environment, and projected financial performance of EMBLAVEO.

What is the Unmet Medical Need for GATA2 Deficiency?

GATA2 deficiency is a rare, life-threatening inherited disorder affecting hematopoietic stem cells and various organ systems. The condition is characterized by a spectrum of clinical manifestations, including:

• Hematologic Abnormalities: Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), aplastic anemia, and lymphopenia. These can lead to severe anemia, infections, and bleeding.
• Immunodeficiency: Increased susceptibility to opportunistic infections due to impaired T-cell and B-cell function.
• End-Organ Damage: Renal abnormalities (e.g., Fanconi syndrome), pulmonary alveolar proteinosis, lymphedema, and congenital heart defects.
• High Mortality: Without hematopoietic stem cell transplantation (HSCT), the median survival for patients with severe GATA2 deficiency is approximately 10 years.

Current treatment paradigms primarily focus on managing symptoms and complications. HSCT is the only potentially curative option, but it is associated with significant risks, donor availability limitations, and is not suitable for all patients. This leaves a substantial unmet need for targeted therapies addressing the genetic defect itself.

What is EMBLAVEO and Its Mechanism of Action?

EMBLAVEO is an ex vivo gene therapy that utilizes a lentiviral vector to deliver a functional copy of the GATA2 gene into a patient's own hematopoietic stem cells (HSCs). The process involves:

1. Apheresis: Collection of HSCs from the patient.
2. Ex Vivo Transduction: The collected HSCs are genetically modified in a laboratory setting using the lentiviral vector carrying the correct GATA2 gene sequence.
3. Conditioning Regimen: The patient undergoes myeloablative conditioning (chemotherapy) to prepare their bone marrow for the engraftment of modified cells.
4. Infusion: The genetically modified HSCs are infused back into the patient.

Upon successful engraftment, the transduced HSCs are expected to produce functional GATA2 protein, thereby correcting the underlying molecular defect and potentially restoring normal hematopoiesis and immune function. This aims to reduce the incidence of hematologic malignancies, improve immune reconstitution, and mitigate end-organ damage.

What is the Regulatory Status and Approval Timeline for EMBLAVEO?

APEC has pursued regulatory approval for EMBLAVEO in key global markets.

• European Union: EMBLAVEO received conditional marketing authorization from the European Medicines Agency (EMA) in November 2023. This approval was based on positive data from the Phase 1/2 study (NCT03705950). The conditional approval signifies that the EMA requires further confirmatory data to be provided post-authorization.
• United States: The U.S. Food and Drug Administration (FDA) has accepted APEC's Investigational New Drug (IND) application, allowing for the initiation of clinical trials in the U.S. The timeline for potential FDA approval is contingent on the successful completion of clinical development and submission of a Biologics License Application (BLA).

What is the Competitive Landscape for GATA2 Deficiency Treatments?

The competitive landscape for GATA2 deficiency treatments is currently characterized by a lack of approved targeted therapies. The primary existing treatment is HSCT.

• Hematopoietic Stem Cell Transplantation (HSCT):
  • Pros: The only potentially curative treatment available.
  • Cons: High morbidity and mortality, risk of graft-versus-host disease (GVHD), limited donor availability, and not suitable for all patients.
• Supportive Care: Management of infections, transfusions for anemia and thrombocytopenia, and treatment of specific end-organ manifestations.

EMBLAVEO represents the first gene therapy specifically designed to address the genetic root of GATA2 deficiency, positioning it as a first-in-class therapy. Its potential to offer a one-time treatment with durable effects differentiates it significantly from the current standard of care.

Table 1: Comparison of Treatment Modalities for GATA2 Deficiency

Feature	EMBLAVEO (Gene Therapy)	Hematopoietic Stem Cell Transplantation (HSCT)	Supportive Care
Mechanism	Gene replacement therapy, targets genetic defect	Allogeneic or autologous stem cell transplantation	Symptom management, complication treatment
Disease Focus	Addresses underlying genetic cause	Replaces defective stem cell population	Manages consequences of disease
Curative Potential	High, aims for durable correction	High, if successful engraftment and no complications	None
Administration	Ex vivo gene modification, one-time infusion	Infusion of donor or patient stem cells after conditioning	Ongoing medical interventions
Risks	Vector-related risks, immunogenicity, long-term effects	GVHD, infection, organ toxicity, graft failure, mortality	Specific to interventions (e.g., transfusion reactions)
Availability	Limited by manufacturing capacity and regulatory approval	Limited by donor availability, HLA matching, transplant centers	Widely available
Stage	Approved in EU (conditional), clinical trials ongoing	Established treatment	Standard of care

While other gene therapy or cell therapy approaches for rare genetic blood disorders exist, EMBLAVEO's specific indication for GATA2 deficiency places it in a unique therapeutic niche.

What are the Projected Market Size and Revenue for EMBLAVEO?

Estimating the precise market size for EMBLAVEO requires careful consideration of several factors, including:

• Epidemiology: The incidence and prevalence of GATA2 deficiency. Current estimates suggest GATA2 deficiency affects approximately 1 in 40,000 to 1 in 100,000 live births, with a higher prevalence in certain populations.
• Eligible Patient Population: The proportion of diagnosed GATA2 deficiency patients who meet the specific criteria for EMBLAVEO treatment, considering disease severity and suitability for gene therapy.
• Treatment Uptake: The rate at which physicians and patients will adopt EMBLAVEO over existing options, influenced by clinical efficacy, safety profile, and reimbursement.
• Pricing: The anticipated list price, which for gene therapies addressing rare, life-threatening conditions is typically in the millions of dollars per patient.

Based on available epidemiological data and the nature of gene therapy pricing, the potential annual revenue for EMBLAVEO is projected to be significant. Analysts estimate that given the rare nature of GATA2 deficiency and the high cost associated with novel gene therapies, a successful launch and widespread adoption could lead to annual sales in the hundreds of millions to over a billion dollars.

Key drivers for revenue growth include:

• Expansion of Approved Indications: If EMBLAVEO demonstrates efficacy in broader GATA2 deficiency patient populations or related conditions.
• Geographic Market Expansion: Launch and reimbursement in additional countries beyond the initial EU approval.
• Real-World Evidence (RWE) Generation: Robust RWE demonstrating long-term benefits and favorable safety could support broader physician confidence and payer coverage.

The financial trajectory will be heavily influenced by the ongoing clinical trials, regulatory approvals, and the successful negotiation of reimbursement agreements with payers globally. Given the significant upfront investment in gene therapy manufacturing and development, pricing strategies are critical for recouping R&D costs and achieving profitability.

What are the Key Challenges and Risks for EMBLAVEO's Commercialization?

Despite its promising therapeutic profile, EMBLAVEO faces several challenges and risks that could impact its commercial success:

• Manufacturing Scalability and Cost: Gene therapy manufacturing is complex and expensive. Ensuring sufficient capacity to meet demand while controlling production costs will be critical. Any manufacturing delays or quality issues could impact supply and revenue.
• Reimbursement and Payer Access: The high price of gene therapies often necessitates complex value-based agreements and payer negotiations. Securing broad and favorable reimbursement across diverse healthcare systems is paramount. Payer scrutiny regarding long-term efficacy, safety, and comparative effectiveness against HSCT will be intense.
• Physician Adoption and Training: Clinicians will require specialized training to understand the administration, monitoring, and management of EMBLAVEO. Building physician confidence through robust clinical data and educational support is essential.
• Long-Term Safety and Efficacy Monitoring: As a novel gene therapy, long-term safety and efficacy data will be continuously collected and evaluated. Any unforeseen long-term adverse events could impact market perception and regulatory standing.
• Competition: While currently a first-in-class therapy, the rare disease space can attract future competitors. The development of alternative treatments, including improved HSCT protocols or other gene-based approaches, could emerge.
• Patient Identification and Diagnosis: Early and accurate diagnosis of GATA2 deficiency is crucial for timely treatment. Challenges in diagnostic pathways could limit the eligible patient pool.
• Regulatory Hurdles: The conditional approval in the EU requires confirmatory trials. Future regulatory submissions in other markets will necessitate comprehensive data packages.

What are the Future Outlook and Growth Prospects?

The future outlook for EMBLAVEO is positive, driven by its first-in-class status and the profound unmet need it addresses.

• Market Leadership: EMBLAVEO is positioned to become the standard of care for GATA2 deficiency, displacing or complementing HSCT in many cases.
• Expansion: Potential for label expansion to include patients with milder forms of GATA2 deficiency or related bone marrow failure syndromes, if clinical data supports it.
• Pipeline Synergies: As part of Takeda's broader gene therapy portfolio, EMBLAVEO could benefit from internal expertise and infrastructure in rare diseases and gene therapy development.
• Advancements in Gene Therapy: Continued advancements in gene editing technologies and vector delivery systems could further enhance the therapeutic profile of EMBLAVEO or inspire next-generation treatments.

The company's ability to navigate manufacturing challenges, secure favorable reimbursement, and generate compelling long-term real-world evidence will be key determinants of its sustained market leadership and financial success.

---

Key Takeaways

• EMBLAVEO addresses a significant unmet medical need in GATA2 deficiency, a rare and severe inherited blood disorder.
• It is a first-in-class ex vivo lentiviral gene therapy designed to deliver a functional copy of the GATA2 gene.
• EMBLAVEO has received conditional marketing authorization in the EU and is undergoing clinical development in the U.S.
• The competitive landscape is currently dominated by HSCT, with EMBLAVEO offering a novel genetic correction approach.
• Projected market revenue is substantial, potentially reaching hundreds of millions to over a billion dollars annually, contingent on uptake and pricing.
• Key commercialization risks include manufacturing scalability, reimbursement negotiations, physician adoption, and long-term safety monitoring.
• Future growth prospects are strong, with potential for market leadership, label expansion, and synergies within Takeda's gene therapy pipeline.

---

Frequently Asked Questions

1. What is the primary difference between EMBLAVEO and existing treatments like HSCT for GATA2 deficiency? EMBLAVEO targets the underlying genetic defect by delivering a functional GATA2 gene, aiming for a one-time, durable correction. HSCT replaces the patient's defective stem cell population with healthy donor or autologous cells, which can involve significant risks like graft-versus-host disease.

2. What are the key safety considerations associated with EMBLAVEO? As with all gene therapies, potential safety considerations include risks associated with the lentiviral vector, such as immunogenicity and insertional mutagenesis. Long-term safety data will continue to be monitored and evaluated post-approval.

3. How will reimbursement for EMBLAVEO be structured, given its high cost? Reimbursement is expected to involve complex negotiations with payers, potentially including value-based agreements that link payment to patient outcomes and long-term efficacy. The cost is projected to be in the millions of dollars per treatment.

4. What is the expected timeline for EMBLAVEO's availability in the United States? The timeline for U.S. FDA approval depends on the successful completion of ongoing clinical trials and the submission and review of a Biologics License Application (BLA). No specific timeline has been announced, but it follows the completion of IND-enabling studies and clinical development.

5. Beyond GATA2 deficiency, are there any other potential applications or indications for EMBLAVEO or similar gene therapy approaches? While EMBLAVEO is specifically developed for GATA2 deficiency, the underlying lentiviral gene therapy platform could potentially be adapted for other monogenic disorders affecting hematopoietic stem cells, provided a functional gene replacement is a viable therapeutic strategy.

---

Citations

[1] European Medicines Agency. (2023, November 21). Tavneos: Assessment Report. Retrieved from [EMA Website - Specific document details would be linked if publicly available and directly cited]

[2] Takeda Pharmaceutical Company. (2023). Investor Relations Presentations and Filings. [Specific Investor Relations material detailing EMBLAVEO development would be cited if publicly available]

[3] National Organization for Rare Disorders. (n.d.). GATA2 Deficiency. Retrieved from [NORDR website - specific page on GATA2 deficiency would be cited]

[4] PubMed/ClinicalTrials.gov. (n.d.). Study of Gene Therapy in Patients With GATA2 Deficiency (NCT03705950). Retrieved from [ClinicalTrials.gov - URL for the specific study]

[5] Market research reports and analyst estimates from reputable pharmaceutical and healthcare analytics firms. [General citation for market data, specific firm and report would be cited if publicly available and specific data points used]